May 11, 2020
Orexo Acquires Exclusive US Rights to Commercialize deprexis®, A World-leading Digital Therapy to Help Patients Manage the Symptoms of Depression
Mar 26, 2020
Orexo Publishes the Annual Report for 2019
Mar 25, 2020
Orexo Has Repurchased 14 Percent of Own Corporate Bonds
Mar 17, 2020
Orexo Presents Sales Potential of the Pharmaceutical Pipeline and Digital Therapies During the Capital Markets Day
Mar 12, 2020
Invitation to Attend Orexo's Capital Markets Day via Teleconference
Feb 17, 2020
Orexo AB (publ.) has Resolved to Carry out Repurchases of own Shares
Dec 03, 2019
Save the Date: Orexo to Host Capital Markets Day focusing on Digital Health, on March 17, 2020
Jul 10, 2019
Orexo Signs License and Supply Agreement With Mundipharma for Zubsolv® in Australia and New Zealand
Jul 09, 2019
Orexo Prepays Part of the Corporate Bond Loan
Jun 28, 2019
Number of Shares and Votes in Orexo
Jun 12, 2019
Issue and Repurchase of Class C Shares
May 31, 2019
Number of Shares and Votes in Orexo
May 17, 2019
Orexo's Closest Upcoming Presentations at Conferences
Apr 26, 2019
Issues of Shares Following the Vesting of 2016/2019 Incentive Plan
Mar 29, 2019
District Court of Delaware Rules that Actavis does not Infringe with their Suboxone® and Subutex® Generics
Mar 21, 2019
Orexo Publishes the Annual Report for 2018
Feb 28, 2019
Number of Shares and Votes in Orexo
Jan 11, 2019
Actavis Infringes Orexo's Long Term Zubsolv® U.S. Patent ´330
Dec 13, 2018
Orexo Regains Rights to Zubsolv® in all Countries Outside the US
Dec 06, 2018
Orexo Hosts Capital Markets Day Today in Stockholm, Sweden